

Nor Eddine Sounni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2376784/publications.pdf>

Version: 2024-02-01

47
papers

3,362
citations

186265

28
h-index

243625

44
g-index

49
all docs

49
docs citations

49
times ranked

5692
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells. <i>Redox Biology</i> , 2022, 53, 102324. | 9.0 | 34 |
| 2 | Estetrol Combined to Progestogen for Menopause or Contraception Indication Is Neutral on Breast Cancer. <i>Cancers</i> , 2021, 13, 2486. | 3.7 | 13 |
| 3 | MO332THE IRRADIATION-INDUCED RENAL ISCHEMIC PRECONDITIONING IS BLUNTED BY THE ORAL ADMINISTRATION OF THE ANTI-ANGIOGENIC AGENT, SUNITINIB. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, . | 0.7 | 0 |
| 4 | Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence. <i>Redox Biology</i> , 2021, 43, 102006. | 9.0 | 102 |
| 5 | Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. <i>Cancers</i> , 2020, 12, 731. | 3.7 | 280 |
| 6 | BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. <i>Science Translational Medicine</i> , 2020, 12, . | 12.4 | 86 |
| 7 | MT4-MMP: The GPI-Anchored Membrane-Type Matrix Metalloprotease with Multiple Functions in Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 354. | 4.1 | 23 |
| 8 | Rewiring of Lipid Metabolism and Storage in Ovarian Cancer Cells after Anti-VEGF Therapy. <i>Cells</i> , 2019, 8, 1601. | 4.1 | 25 |
| 9 | Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 1838-1850. | 7.0 | 41 |
| 10 | Stromal integrin $\alpha 11$ regulates PDGFR β signaling and promotes breast cancer progression. <i>Journal of Clinical Investigation</i> , 2019, 129, 4609-4628. | 8.2 | 102 |
| 11 | Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 2605-2615. | 7.0 | 45 |
| 12 | Microenvironment-derived ADAM28 prevents cancer dissemination. <i>Oncotarget</i> , 2018, 9, 37185-37199. | 1.8 | 8 |
| 13 | MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib. <i>British Journal of Cancer</i> , 2017, 116, 742-751. | 6.4 | 13 |
| 14 | Degradomic and yeast 2-hybrid inactive catalytic domain substrate trapping identifies new membrane-type 1 matrix metalloproteinase (MMP14) substrates: CCN3 (Nov) and CCN5 (WISP2). <i>Matrix Biology</i> , 2017, 59, 23-38. | 3.6 | 29 |
| 15 | Dusp3 deletion in mice promotes experimental lung tumour metastasis in a macrophage dependent manner. <i>PLoS ONE</i> , 2017, 12, e0185786. | 2.5 | 14 |
| 16 | Dynamics of internalization and recycling of the prometastatic membrane type 4 matrix metalloproteinase (MT4-MMP) in breast cancer cells. <i>FEBS Journal</i> , 2016, 283, 704-722. | 4.7 | 15 |
| 17 | The timing of surgery after neoadjuvant radiotherapy influences tumor dissemination in a preclinical model. <i>Oncotarget</i> , 2015, 6, 36825-36837. | 1.8 | 7 |
| 18 | EGFR Activation and Signaling in Cancer Cells Are Enhanced by the Membrane-Bound Metalloprotease MT4-MMP. <i>Cancer Research</i> , 2014, 74, 6758-6770. | 0.9 | 33 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Blocking Lipid Synthesis Overcomes Tumor Regrowth and Metastasis after Antiangiogenic Therapy Withdrawal. <i>Cell Metabolism</i> , 2014, 20, 280-294. | 16.2 | 141 |
| 20 | Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice. <i>Nature Protocols</i> , 2013, 8, 2197-2211. | 12.0 | 283 |
| 21 | New prospects in the roles of the C-terminal domains of VEGF-A and their cooperation for ligand binding, cellular signaling and vessels formation. <i>Angiogenesis</i> , 2013, 16, 353-371. | 7.2 | 51 |
| 22 | Targeting the Tumor Microenvironment for Cancer Therapy. <i>Clinical Chemistry</i> , 2013, 59, 85-93. | 3.2 | 280 |
| 23 | Towards Lipidomics of Low-Abundant Species for Exploring Tumor Heterogeneity Guided by High-Resolution Mass Spectrometry Imaging. <i>International Journal of Molecular Sciences</i> , 2013, 14, 24560-24580. | 4.1 | 25 |
| 24 | Sunitinib Inhibits Inflammatory Corneal Lymphangiogenesis. , 2013, 54, 3082. | | 55 |
| 25 | New and Paradoxical Roles of Matrix Metalloproteinases in the Tumor Microenvironment. <i>Frontiers in Pharmacology</i> , 2012, 3, 140. | 3.5 | 88 |
| 26 | The proteolytic activity of MT4â€MMP is required for its proâ€angiogenic and proâ€metastatic promoting effects. <i>International Journal of Cancer</i> , 2012, 131, 1537-1548. | 5.1 | 24 |
| 27 | Lymphangiogenesis in post-natal tissue remodeling: Lymphatic endothelial cell connection with its environment. <i>Molecular Aspects of Medicine</i> , 2011, 32, 146-158. | 6.4 | 56 |
| 28 | MT-MMPS as Regulators of Vessel Stability Associated with Angiogenesis. <i>Frontiers in Pharmacology</i> , 2011, 2, 111. | 3.5 | 64 |
| 29 | Unimpeded skin carcinogenesis in K14â€HPV16 transgenic mice deficient for plasminogen activator inhibitor. <i>International Journal of Cancer</i> , 2011, 128, 283-293. | 5.1 | 15 |
| 30 | Exploration of MMP Function in Mouse Models of Angiogenesis. , 2011, , 105-115. | | 0 |
| 31 | Timpâ€2 binding with cellular MT1â€MMP stimulates invasionâ€promoting MEK/ERK signaling in cancer cells. <i>International Journal of Cancer</i> , 2010, 126, 1067-1078. | 5.1 | 57 |
| 32 | Stromal regulation of vessel stability by MMP14 and TGFÎ². <i>DMM Disease Models and Mechanisms</i> , 2010, 3, 317-332. | 2.4 | 82 |
| 33 | Development of an optimized activatable MMP-14 targeted SPECT imaging probe. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 653-659. | 3.0 | 61 |
| 34 | Epigenetic Control of the Invasion-promoting MT1-MMP/MMP-2/TIMP-2 Axis in Cancer Cells. <i>Journal of Biological Chemistry</i> , 2009, 284, 12727-12734. | 3.4 | 95 |
| 35 | Biochemical evidence of the interactions of membrane type-1 matrix metalloproteinase (MT1-MMP) with adenine nucleotide translocator (ANT): potential implications linking proteolysis with energy metabolism in cancer cells. <i>Biochemical Journal</i> , 2009, 420, 37-47. | 3.7 | 10 |
| 36 | Membrane-Type 4 Matrix Metalloproteinase Promotes Breast Cancer Growth and Metastases. <i>Cancer Research</i> , 2006, 66, 5165-5172. | 0.9 | 61 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Membrane type-matrix metalloproteinases and tumor progression. <i>Biochimie</i> , 2005, 87, 329-342. | 2.6 | 127 |
| 38 | Up-regulation of Vascular Endothelial Growth Factor-A by Active Membrane-type 1 Matrix Metalloproteinase through Activation of Src-Tyrosine Kinases. <i>Journal of Biological Chemistry</i> , 2004, 279, 13564-13574. | 3.4 | 126 |
| 39 | Anti-Invasive, Antitumoral, and Antiangiogenic Efficacy of a Pyrimidine-2,4,6-trione Derivative, an Orally Active and Selective Matrix Metalloproteinases Inhibitor. <i>Clinical Cancer Research</i> , 2004, 10, 4038-4047. | 7.0 | 148 |
| 40 | Membrane associated proteases and their inhibitors in tumour angiogenesis. <i>Journal of Clinical Pathology</i> , 2004, 57, 577-584. | 2.0 | 96 |
| 41 | Crystal Structure of the Catalytic Domain of MMP-16/MT3-MMP: Characterization of MT-MMP Specific Features. <i>Journal of Molecular Biology</i> , 2004, 336, 213-225. | 4.2 | 37 |
| 42 | Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis. <i>Matrix Biology</i> , 2003, 22, 55-61. | 3.6 | 116 |
| 43 | MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. <i>FASEB Journal</i> , 2002, 16, 555-564. | 0.5 | 234 |
| 44 | Expression of membrane type 1 matrix metalloproteinase (MT1-MMP) in A2058 melanoma cells is associated with MMP-2 activation and increased tumor growth and vascularization. <i>International Journal of Cancer</i> , 2002, 98, 23-28. | 5.1 | 48 |
| 45 | New Functions of Stromal Proteases and Their Inhibitors in Tumor Progression. <i>Surgical Oncology Clinics of North America</i> , 2001, 10, 417-432. | 1.5 | 22 |
| 46 | Membrane Type 1 Matrix Metalloproteinase-associated Degradation of Tissue Inhibitor of Metalloproteinase 2 in Human Tumor Cell Lines. <i>Journal of Biological Chemistry</i> , 2000, 275, 11368-11378. | 3.4 | 84 |
| 47 | Molecular interactions involving urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), as new targets for tumour therapy. <i>Expert Opinion on Therapeutic Targets</i> , 1999, 3, 469-481. | 1.0 | 5 |